Jump to content

Page values for "Methimazole"

"Medicines" values

1 row is stored for this page
FieldField typeValue
genericStringMethimazole (thiamazole)
brandStringTapazole; outside US Mercazole
structureFile
classesList of String, delimiter: ,[[:Category:Antithyroid_agents|Antithyroid agent]] [[:Category:Thionamides|Thionamide]]
mechanismString'"`UNIQ--vote-00000ECD-QINU`"' Agranulocytosis is the most-feared adverse effect (~0.3%, usually first 90 days of treatment; warn patients to seek urgent CBC for fever or severe sore throat). Hepatotoxicity is class-recognized but more often associated with PTU'"`UNIQ--ref-00000ECE-QINU`"'.
usesString'"`UNIQ--vote-00000ECF-QINU`"', '"`UNIQ--vote-00000ED0-QINU`"', '"`UNIQ--vote-00000ED1-QINU`"', '"`UNIQ--vote-00000ED2-QINU`"'
starting_doseString10-40 mg PO daily depending on hyperthyroidism severity; titrate by clinical and biochemical response (target TSH/free T4)
preparationsString5, 10 mg tablets
fda_maxString60 mg/d typical
pill_idText
routesList of String, delimiter: ,Oral
onsetStringBiochemical improvement within 2-4 weeks; full euthyroid state 6-12 weeks
durationString24 hours
halflifeString~4-6 hours (plasma); intrathyroidal accumulation gives a much longer functional duration'"`UNIQ--ref-00000ED3-QINU`"'
bioavailabilityString~93% (oral)'"`UNIQ--ref-00000ED4-QINU`"'
pregnancyString
legalString[[USLegal:Prescription only|Rx-only]] in US